Glanzmann Thrombasthenia (GT) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Glanzmann Thrombasthenia (GT) Market Outlook

Thelansis’s “Glanzmann Thrombasthenia (GT) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Glanzmann Thrombasthenia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Glanzmann Thrombasthenia (GT) Overview

Glanzmann Thrombasthenia (GT) is a genetic bleeding disorder caused by mutations in the ITGA2B or ITGB3 gene. The disorder results in quantitative and qualitative abnormalities of the integrin alphaIIb/beta3 (αIIbβ3) receptor protein, which is necessary for platelet aggregation and clot formation. The deficiency or dysfunction of αIIbβ3 leads to the inability of platelets to bind together and form clots, causing moderate to severe bleeding. The disorder has been classified into three types based on the availability of αIIbβ3. Type I is the most common, with less than 5% of normal αIIbβ3 levels. Type II has 5-20% of normal levels, and the variant type has adequate levels but only nonfunctional αIIbβ3. In some cases, the cause of the disorder is unknown. The diagnostic features of Glanzmann Thrombasthenia include the absence of platelet aggregation and recurring episodes of mucocutaneous and spontaneous bleeding. Purpura, epistaxis, and gingival bleeding are common manifestations, and red blood cell transfusions may be required in severe cases. The onset of symptoms can occur shortly after birth, and most patients are diagnosed before age 5. The risk of severe bleeding decreases with age, but fatal bleeding episodes can occur at any point in the lifespan of a patient with GT.

• In general population prevalence of glanzmann thrombasthenia estimated to be 1 per 1,000.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: